WallStSmart

Meta Platforms Inc. (META)vsTNL Mediagene Ordinary Shares (TNMG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Meta Platforms Inc. generates 404474% more annual revenue ($200.97B vs $49.67M). META leads profitability with a 30.1% profit margin vs -167.9%. META earns a higher WallStSmart Score of 75/100 (B).

META

Strong Buy

75

out of 100

Grade: B

Growth: 7.3Profit: 10.0Value: 8.0Quality: 7.0
Piotroski: 3/9Altman Z: 2.88

TNMG

Avoid

35

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 4/9Altman Z: -3.80
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

METAUndervalued (+30.1%)

Margin of Safety

+30.1%

Fair Value

$875.05

Current Price

$611.91

$263.14 discount

UndervaluedFair: $875.05Overvalued

Intrinsic value data unavailable for TNMG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

META6 strengths · Avg: 9.7/10
Market CapQuality
$1.55T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.2%10/10

Every $100 of equity generates 30 in profit

Profit MarginProfitability
30.1%10/10

Keeps 30 of every $100 in revenue as profit

Operating MarginProfitability
41.3%10/10

Strong operational efficiency at 41.3%

Free Cash FlowQuality
$14.83B10/10

Generating 14.8B in free cash flow

PEG RatioValuation
1.008/10

Growing faster than its price suggests

TNMG1 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

META1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TNMG4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.63M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-164.6%2/10

ROE of -164.6% — below average capital efficiency

Free Cash FlowQuality
$-1.86M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : META

The strongest argument for META centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 30.1% and operating margin at 41.3%. Revenue growth of 23.8% demonstrates continued momentum.

Bull Case : TNMG

The strongest argument for TNMG centers on Price/Book.

Bear Case : META

The primary concerns for META are Piotroski F-Score.

Bear Case : TNMG

The primary concerns for TNMG are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

META profiles as a growth stock while TNMG is a turnaround play — different risk/reward profiles.

TNMG carries more volatility with a beta of 1.41 — expect wider price swings.

META is growing revenue faster at 23.8% — sustainability is the question.

META generates stronger free cash flow (14.8B), providing more financial flexibility.

Bottom Line

META scores higher overall (75/100 vs 35/100), backed by strong 30.1% margins and 23.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Meta Platforms Inc.

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.

Visit Website →

TNL Mediagene Ordinary Shares

COMMUNICATION SERVICES · PUBLISHING · USA

TNL Mediagene Ordinary Shares is a forward-thinking biopharmaceutical company dedicated to the development and commercialization of cutting-edge medical therapies aimed at addressing significant unmet medical needs, particularly in the fields of oncology and autoimmune disorders. With a robust pipeline leveraging advanced technologies and strategic partnerships, the company is well-positioned for substantial growth in the dynamic healthcare landscape. TNL Mediagene's unwavering commitment to scientific research and innovative approaches underpins its mission to improve patient outcomes, establishing it as a prominent entity in the biopharmaceutical industry.

Visit Website →

Want to dig deeper into these stocks?